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Rationale: High-mobility group box 1 (HMGB1) is a potent inflam-
matory mediator elevated in sepsis and rheumatoid arthritis, al-
though its role in cystic fibrosis (CF) lung disease is unknown.
Objectives: To determine whether HMGB1 contributes to CF lung
inflammation, including neutrophil chemotaxis and lung matrix
degradation.
Methods: We used sputum and serum from subjects with CF and
a Scnn1b-transgenic (Scnn1b-Tg) mousemodel thatoverexpresses b-
epithelial Na1 channel in airways and mimics the CF phenotype,
including lung inflammation. Human secretions and murine bron-
choalveolar lavage fluid (BALF) was assayed for HMGB1 by Western
blot and ELISA. Neutrophil chemotaxis was measured in vitro after
incubation with human neutrophils. The collagen fragment proline-
glycine-proline (PGP) was measured by tandem mass spectroscopy.
Measurements and Main Results: HMGB1was detected in CF sputumat
higher levels than secretions from normal individuals. Scnn1b-Tg
mice had elevated levels of HMGB1 by Western blot and ELISA. We
demonstrated that dose-dependent chemotaxis of human neutro-
phils stimulated by purified HMGB1 was partially dependent on CXC
chemokine receptors and that this could be duplicated in CF sputum
and BALF from Scnn1b-Tg mice. Neutralization by anti-HMGB1
antibody, in both the sputum and BALF-reduced chemotaxis, which
suggested that HMGB1contributed to the chemotactic properties of
these samples. Intratracheal administration of purified HMGB1
induced neutrophil influx into the airways of mice and promoted
the release of PGP. PGP was also elevated in Scnn1b-Tg mice and CF
serum.
Conclusions: HMGB1 expression contributes to pulmonary inflam-
mation and lung matrix degradation in CF airway disease and
deserves further investigation as a biomarker and potential thera-
peutic target.
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High-mobility group box 1 (HMGB1) is a late mediator of the
systemic inflammatory response syndrome (SIRS) and is ele-
vated in bacterial sepsis and hemorrhagic shock (1–3). Under
normal conditions, HMGB1 serves as a transcription factor that
is expressed in the nucleus of a wide variety of cell types. In
inflammatory states, HMGB1 is released into the extracellular
environment by stimulated macrophages through a nonclassical
pathway (4, 5), activating acute inflammation through Toll-like
receptor (TLR)-2, TLR-4, and receptor for advanced glycation
end products (RAGE) (5–7). HMGB1 is also released by cells
undergoing necrosis (8), a mechanism proposed to explain its
effects on perpetuating systemic inflammation in conditions in
which cell death is prominent (9) although release during
apoptosis has also been reported (10). Extracellular HMGB1
has pleomorphic effects on multiple organs in models of sepsis
and shock including activation of nuclear factor (NF)-kB,
diffuse endothelial activation, pulmonary inflammation remi-
niscent of the adult respiratory distress syndrome, hepatocellu-
lar injury, and systemic activation of inflammatory cells (7, 9,
11). HMGB1 kinetics in sepsis indicates its role as a late
inflammatory mediator, increasing only after tumor necrosis
factor (TNF)-a and IL-1b have peaked (9), making it an
attractive therapeutic target. Inhibitors of the inflammatory
activities of HMGB1 have been efficacious in animal models
(12–15), and are currently in preclinical development.
Previous studies defining the role of HMGB1 in the lung have
included acute inflammatory states, such as in hemorrhage and
septic shock, and an animal model of ventilator-induced lung injury,
as well as induction of an adult respiratory distress syndrome–like
phenotype after direct instillation (2, 14). HMGB1 has also been
implicated in chronic inflammatory conditions such as rheumatoid
arthritis (16, 17). Given the importance of HMGB1 with regard to
innate immunity, we hypothesized that this protein may also have
effects on the prominent neutrophilic inflammatory response that
characterizes cystic fibrosis (CF) airway disease (18, 19), and could
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
High mobility group box 1 (HMGB1) is elevated in cystic
fibrosis airways, significantly contributes to neutrophil in-
flux, and contributes to lung matrix degradation.
What This Study Adds to the Field
We show that HMGB1 contributes to pulmonary inflam-
mation and lung matrix degradation in cystic fibrosis, and
that it may be a potential biomarker and therapeutic target.
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contribute to lung matrix degradation and lung structure damage
that characterize progression of the disease (20).
To evaluate the potential role of HMGB1 in CF lung disease,
and consequently as a biomarker and potential therapeutic target,
we examined expression levels and the biological activity of
HMGB1 in samples derived from patients with CF and from
a murine model of CF lung disease (Scnn1b-transgenic [Scnn1b-
Tg] mouse) characterized by chronic neutrophilic inflammation
and airway mucus obstruction (21). We also examined whether
HMGB1-related activity led to lung matrix degradation that could
be measured through a simple, noninvasive technique. We found
increased expression of HMGB1 in human subjects with CF and in
Scnn1b-Tg mice, and demonstrated its pathogenic role as a neu-
trophil chemoattractant partly dependent on a CXCR2-dependent
mechanism capable of production of the bioactive collagen
fragment proline-glycine-proline (PGP), a lung matrix degrada-
tion product that also directly activates neutrophils through CXCR
receptors (22). Some of the results of these studies have been
previously reported in the form of abstracts (23, 24).
METHODS
Special Reagents
Anti-HMGB1 antibodies were purchased either from Abcam (Abcam,
Cambridge, UK) or R&D Systems (Minneapolis, MN). ELISA was
performed using commercially available kits (first-generation assay;
Shino Test Corp., Tokyo, Japan). Recombinant human HMGB1 was
purchased from Sigma-Aldrich Chemical Corporation (St. Louis, MO)
at greater than 90% purity and concentration confirmed by ELISA.
Animal Models
Scnn1b-Tg mice, 5–6 weeks of age, and littermate control mice were
acquired in collaboration with the University of North Carolina Cystic
Fibrosis Center (Chapel Hill, NC), and evaluated at 5–6 weeks of age.
Male C3H/HeJ and BALB/c mice, 5–6 weeks of age, were purchased
from Jackson Laboratory (Bar Harbor, ME).
Intratracheal Administration of HMGB1
Methoxyfluorane-anesthetized C3H/HeJ and BALB/c mice received 25
or 50 mg HMGB1 intratracheally in 50 ml of sterile phosphate-buffered
saline (PBS). Control mice were given 50 ml sterile PBS intratracheally
without HMGB1, as previously described (2). After 24 hours of
observation with a light incubator, mice were killed and bronchoalveo-
lar lavage (BAL) performed.
Murine BAL
For Scnn1b-Tg and littermate control mice, after avertin (2,2,2
tribromophenol) anesthesia and exsanguination, a tracheal canula
was inserted and BAL performed in three or four body weight
instillations of PBS (0.035 ml/g) and pooled as previously described
(21). BAL in BALB/c and C3H/HeJ mice was performed similarly,
except medroxyfluorane was used for anesthesia, and the BAL pro-
cedure was performed under direct visualization of lung distension
(maximum 1 ml), as previously described (22). Cells were pelleted by
centrifugation (500–1,100 3 g for 5 min at 48 C) and resuspended in
100–150 ml PBS for total cell count determination. Cytospin prepara-
tions were stained with modified Wright-Giemsa staining for differen-
tial cell counts. Aliquots of cell-free BAL fluid (BALF) (supernatant)
were prepared and stored at 2808C for further assay.
Human Sample Preparation
Freshly collected sputum after cough induction was diluted 1:1 in sterile saline
and centrifuged at 1,000 3 g for 20 minutes. The resultant supernatants were
collected and stored in aliquots at 2808C, as previously reported (25–27).
Western Blot Analysis
Western blotting was used to determine the presence of HMGB1 in the
human sputum and murine BALF. Total protein concentration of
human samples was measured using Bio-Rad Benchmark Plus Multi-
plate Spectrophotometer (Bio-Rad, Hercules, CA), and samples were
normalized, as previously described (2). Twenty micrograms of total
proteins/sample were loaded on a 12% Tris-HCl–sodium dodecyl
sulfate–polyacrylamide gel and run for 1 hour at 120 V. Protein was
electrotransferred to a nitrocellulose membrane and then blocked with
5% nonfat dry milk and Tris-buffered saline (composition, pH) with
0.1% Tween 20. After being blocked, the membrane was incubated
overnight at 48C with a specific monoclonal mouse primary antibody to
HMGB1 (R&D Systems) at a dilution of 1:2,000 followed by anti-
mouse horseradish peroxidase–coupled secondary antibody (Bio-Rad)
at a dilution of 1:10,000. After three washings, bands were detected
using Enhanced Chemiluminescence Plus Western blotting detection
reagents (Amersham Pharmacia Biotech, Piscataway, NJ), as pre-
viously reported (27). HMGB1 levels were then estimated by compar-
ing with purified HMGB1.
ELISA
Immunoreactive HMGB1 was quantified using a commercially available
capture ELISA using polyclonal and monoclonal antibody (e.g., Shino
Test Corp.), as previously described by our center and others (2, 3).
Results were quantified using a relative standard curve method with
purified human HMGB1 per the manufacturer’s instructions. All BAL
samples were run without dilution and in duplicate for verification using
the Bio-Rad Benchmark Plus Multiplate Spectrophotometer (Bio-Rad).
Human Neutrophil Chemotaxis
In vitro chemotaxis assays of mouse and human samples were
performed using isolated human neutrophils in a 96-well modified
Boyden chamber appropriate for the evaluation of leukocyte chemo-
taxis. Human neutrophils were isolated from peripheral blood by
standard methods using Histopaque 1077 and 1119, as previously
described (22). Cells were washed twice with Hanks’ balanced salt
solution containing 1% bovine serum albumin (BSA), counted, and
resuspended at 2 3 106 cells/ml in Dulbecco’s modified Eagle medium
(DMEM) with 5% BSA (all chemicals from Sigma-Aldrich, except
where noted). Murine neutrophils were isolated by bone marrow
aspiration and centrifugation on 62% Percoll at 1,000 3 g for
30 minutes at room temperature. Pelleted cells were collected,
subjected to red blood cell lysis with AKC lysis buffer (Biosource
International, Camarillo, CA), and resuspended in DMEM with 5%
BSA as previously described (28). In vitro assays were then performed
in a 96-well polycarbonate filter plate with a 3-mm pore size appropri-
ate for leukocyte chemotaxis (Millipore, Billerica, MA). Cell solution
(100 ml) was added to each well in the top filter-plate portion of the
assembly, and 150 ml of diluted sample in DMEM was added to the
bottom feeder wells. CF sputum was added in 1:10 dilution and
incubated with 0.4 mg of neutralizing antibody (antibody [ab] 18256;
Abcam, Cambridge, UK) or isotype control at room temperature for
2 hours before chemotaxis assay. After 1 hour incubation at 378C with
5% CO2, the upper portion was removed, and four photomicrographs
(20) per well were digitally acquired with a Nikon Eclipse TE2000-U
inverted microscope (Nikon, Melville, NY) interfaced with a Nikon
Coolpix 990 digital camera. Polymorphonuclear leukocyte (PMN)
counts were made by averaging the four images as previously described
(22, 29). All experiments were run in duplicate for verification. Murine
BALF experiments were performed similarly using anti-HMGB1
antibody acquired from R&D Systems. For comparison between
experiments, data were standardized to a chemotactic index with cell
migration to blank medium as a baseline (e.g., chemotactic index 5
mean cells per field migrating to sample solution per mean cells per
field migrating to blank medium). IL-8 was used as a positive control
(10–50 ng/ml). Chemokinesis experiments were preformed using
varying amounts of HMGB1 in the upper chamber with a fixed
concentration of HMGB1 in the lower chamber. Blockade of CXCR1
and CXCR2 neutrophil receptors was performed by preincubating
isolated neutrophils with antibody (25 mg/ml, R&D Systems) for
45 minutes at 48C before assay.
Electron Ionization–Liquid Chromatography Tandem Mass
Spectrometry for PGP Detection
PGP was measured in sputum and BALF samples using an MDS Sciex
(Applied Biosystems, Foster City, CA) API-4000 spectrometer equipped
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with a Shimadzu HPLC (Shimadzu Scientific Instruments, Columbia,
MD). HPLC was performed using a 2.1 3 150 mm Develosi C30
column with 0.1% formic acid (solution A) and acetonitrile 1 0.1%
formic acid (solution B). From 0 to 0.6 minutes after sample loading,
a gradient was applied containing 20% solution B, and from 0.6 to 5
minutes after sample loading the gradient was increased to 100%
solution B. Background was removed by flushing with 100% isopro-
pranol 1 0.1% formic acid. Positive electrospray mass transitions were
at 270–70 and 270–116 M/z for PGP. Area under the curve was
measured, and PGP concentration calculated using a relative standard
curve method as previously described (22). Serum samples were
processed by filtering through a Millipore 10,000 Molecular Weight
cutoff centrifugal filter, then washing with 30 ml of 1 N HCl. Filtrates
were evaluated by spectroscopy as noted above.
Study Population
All subjects with CF were diagnosed using accepted diagnostic criteria,
including a minimum of two clinical features consistent with the
diagnosis and either two sweat Cl2 values greater than 60 mEq or
two disease-causing CF transmembrane conductance regulator (CFTR)
mutations (30). Individuals with CF hospitalized for acute pulmonary
exacerbation (APE) had at least four of the following criteria: 10% or
greater decrease in baseline FEV1, increased cough or sputum pro-
duction, change in sputum character, dyspnea, tachypnea, fever, weight
loss, 5% or greater decrease in O2 saturation, new or worsening
crackles on lung auscultation, or findings on chest X-ray consistent
with pneumonia (31). Secretions from normal subjects were collected
from nonsmoking individuals without known lung disease.
Statistical Analysis
For Western blot densitometry, ELISA, and neutrophil chemotaxis
measures, descriptive statistics (mean, SD, and SEM) and paired and
unpaired t tests or analysis of variance were performed, as appropriate,
using SPSS software (SPSS, Inc., Chicago, IL) and Microsoft Excel
(Microsoft Corp., Seattle, WA). Correlation coefficients were deter-
mined using simple linear regression. All statistical tests were two-
sided and were performed at a 5% significance level (i.e., a 5 0.05).
Assurances
All human samples were obtained from subjects with CF who granted
written informed consent through protocols approved by the Univer-
sity of Alabama at Birmingham Institutional Review Board and the
General Clinical Research Center. All animals were maintained using
approved protocols of the University of Alabama at Birmingham or the
University of North Carolina at Chapel Hill.
RESULTS
HMGB1 Is Elevated in CF Sputum
To test whether HMGB1 is elevated in human CF lung disease,
we compared HMGB1 expression in sputum from subjects with
CF suffering from APE (a population known to have intense
neutrophilic inflammation in the airways [18, 20]) with stable
CF patients presenting for routine outpatient evaluation and
normal controls (Table 1). Western blot analysis showed high
levels of HMGB1 in subjects with CF and with APE, whereas
HMGB1 was essentially undetectable in healthy control sub-
jects (Figure 1A). Evaluation of sputum from outpatients with
stable CF demonstrated intermediate results (Figure 1B).
Densitometry estimated an approximate 10-fold increase in
relative abundance in patients with CF with APE and a twofold
greater expression in outpatients with CF (Figure 1C). Relative
concentrations of HMGB1 negatively correlated with the
duration of systemic antibiotic therapy in inpatients with CF
and with APE (Figure 1D), suggesting that the abundance of
HMGB1 decreases as airway inflammation abates. Although
HMGB1 levels in inpatients with CF were not correlated with
lung function measurements (FEV1% predicted or FVC%
predicted) upon admission, when both inpatient and outpatient
subjects with CF were included, a significant negative correla-
tion was observed (r 5 20.44, P , 0.05).
Elevated HMGB1 in a Model of CF Airway Disease
To explore the relevance of HMGB1-mediated inflammation in
an in vivo system that would allow mechanistic studies, we
investigated a murine model of chronic bronchitis or CF lung
disease. Because DF508 and CFTR knockout mice exhibit
predominantly gastrointestinal pathology and minimal airway
disease (32), we used a mouse model in which airway-targeted
overexpression of the b subunit of the epithelial Na1 channel
causes hyperabsorption of Na1, dehydration of the airway
surface liquid, impaired mucociliary clearance, and an airway
obstructive phenotype closely resembling the human CF phe-
notype, except with no evidence of bacterial colonization with
Pseudomonas aeruginosa (21). As assayed by BAL, Scnn1b-Tg
mice had 33% higher total leukocyte count, and greater
neutrophil and eosinophil counts than wild-type (WT) litter-
mates (Figure 2A). HMGB1 levels were significantly elevated in
BALF of Scnn1b-Tg mice, as assayed by Western blot (Figures
2B and 2C). Use of an ELISA protocol designed for detection
of HMGB1 in serum and plasma confirmed significantly ele-
vated levels of HMGB1 in BALF obtained from Scnn1b-Tg
mice, and indicated that HMGB1 was present at concentrations
anticipated to have proinflammatory activity (Figure 2D; 61.8
and 40.6 ng/ml in Scnn1b-Tg and WT littermates, respectively).
Chemotactic Activity of HMGB1 In Vitro
To evaluate whether the levels of HMGB1 detected in subjects
with CF and Scnn1b-Tg mice contributed to neutrophil influx
into the airways, we evaluated the chemotactic activity of
recombinant HMGB1 for human neutrophils in vitro. Recom-
binant purified HMGB1 induced dose-dependent chemotaxis
(as opposed to chemokinesis) of isolated human neutrophils
(Figures 3A and 3B), but had no effect on chemotaxis of
purified murine neutrophils (data not shown) despite signif-
icant homology between human and murine protein sequence
(.95% homology between human and mouse HMGB1). Spu-
tum from subjects with CF and APE was highly chemotactic for
human neutrophils (14-fold more than control subjects) and was
partially inhibited by preincubation with polyclonal anti-
HMGB1 neutralizing antibody (Figure 3C). Cell-free BALF
from Scnn1b-Tg mice also exhibited increased chemotactic
activity for human neutrophils (although less potently than CF
TABLE 1. DEMOGRAPHIC CHARACTERISTICS OF SUBJECTS WITH
CYSTIC FIBROSIS AND ACUTE PULMONARY EXACERBATION
Patients with CF and APE Outpatients with CF
(n 5 23) (n 5 9)
Age, yr 27.1 6 6.6 25.8 6 7.0
Females, n (%) 6 (31.6) 7 (64.0)
FEV1, % predicted 33.5 6 13.4 60.3 6 15.1
FVC, % predicted 45.1 6 14.1 73.9 6 23.1
Colonized with Pseudomonas
aeruginosa, n (%)
17 (89.5) 9 (81.8)
Genotype (alleles), n (%)
DF508 21 (55.3) 14 (63.6)
Unknown/not identified 13 (34.2) 1 (4.5)
Other 4 (10.5) 8 (31.9)
Definition of abbreviations: APE 5 acute pulmonary exacerbation; CF 5 cystic
fibrosis.
Values are mean 6 SD or n (%).
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sputum) compared with WT BALF (Figure 3D). Preincubation
of BALF from Scnn1b-Tg mice with anti-HMGB1 monoclonal
antibody reduced neutrophil chemotaxis to levels seen with WT
BALF. To more precisely define the mechanistic basis of
HMGB1-induced neutrophil chemotaxis seen in human and
murine biologic samples, we next tested chemotaxis induced by
purified HMGB1 after blockade of CXCR1 and CXCR2
receptors. Human neutrophil chemotaxis for purified HMGB1
was significantly reduced after blockade of CXCR2 (but not
CXCR1) receptors by neutralizing antibodies (Figure 3E),
indicating the importance of this pathway in human samples.
Greater chemotaxis seen by CF sputum compared with murine
BALF may have been due in part to dilution, as total protein
concentration in sputum were 2.99 6 0.38 mg/ml compared with
0.73 6 0.05 mg/ml and 0.63 6 0.03 mg/ml in Scnn1b-Tg and WT
mice, respectively.
Collagen Fragmentation Related to In Vivo HMGB1 Activity
To determine whether purified HMGB1 sufficient to elicit an
inflammatory response in the lung was associated with down-
stream effects relevant to CF pulmonary disease, we intra-
tracheally instilled purified (prokaryotic derived) HMGB1 and
evaluated the inflammatory PMN infiltrate by BAL. At 24 hours
Figure 1. High-mobility group box 1
(HMGB1) levels are elevated in sputum
from subjects with cystic fibrosis (CF) and
inversely correlated with the duration of
intravenous antimicrobial therapy.
HMGB1 detected by Western blot in
spontaneously expectorated sputum
from (A) subjects with CF hospitalized
for CF exacerbation and (B) outpatients
with CF was significantly greater than
airway secretions from normal subjects.
HMGB1 has a calculated molecular
weight of 24.9 kD and migrates as
a 29-kD band under sodium dodecyl
sulfate–polyacrylamide gel electrophore-
sis conditions. Albumin loading control is
shown for comparison. (C) Summary
data of densitometry results showing
that HMGB1 levels were significantly
elevated in sputa from patients with CF
than in secretions from healthy control
subjects. All specimens were standard-
ized for total protein concentration and
compared by relative densitometry; *P ,
0.001, **P , 0.05; n 5 5 controls, 23
inpatients with CF, and 9 outpatients
with CF, 6SEM. (D) HMGB1 levels in
sputum from patients with CF quantified
by Western blot densitometry were in-
versely correlated with the number of
days subject was hospitalized for intrave-
nous antimicrobial therapy, reflecting re-
duced levels of HMGB1 after systemic
antibiotic therapy; r 5 20.51, P , 0.05.
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after instillation, HMGB1 induced dose-dependent influx of
PMNs into the airways (Figure 4). As previously described,
this finding was similar in both BALB/c (Figure 4A) and
endotoxin (LPS)-resistant C3H/HeJ mice (Figure 4B), confirm-
ing that results were independent of possible LPS contamina-
tion (2). Macrophage or lymphocyte influx was not observed in
either mouse strain.
Because the influx of neutrophils and induction of inflam-
mation by HMGB1 might be expected to induce extracellular
matrix turnover by activation of NF-kB (signaling) (33) and the
release of matrix metalloproteinases 8 and 9 into the airway (25,
34), thus contributing to chronic bronchitis and structural
damage seen in CF, we evaluated BALF of C3H/HeJ mice
administered purified HMGB1 for the collagen breakdown
product PGP. PGP is a tripeptide collagen fragment that results
from lung matrix degradation and has been shown to be an IL-8
cogener that induces neutrophil chemotaxis through a CXCR-
dependent mechanism (22). PGP levels detected using electron
ionization–liquid chromatography tandem mass spectrometry
were 2.3-fold greater in C3H/HeJ mice administered 25 mg
HMGB1 compared with animals administered PBS (Figure 5A,
189.7 vs. 80.7 pg/ml in C3H/HeJ). PGP levels were also
significantly elevated in BALF samples from Scnn1b-Tg mice,
whereas in WT littermates, PGP levels were much lower and
often below the limit of detection (Figures 5B and 5C; 48.0 vs.
9.6 pg/ml in Scnn1b-Tg mice and WT controls, respectively).
Using a protocol adapted to measure PGP in human serum,
we also found elevated levels of PGP in subjects with CF and
APE (1,076 pg/ml) compared with non-CF control subjects
(563 pg/ml) (Figure 5D).
DISCUSSION
We show that the acute inflammatory mediator HMGB1 is
significantly elevated in the sputum of humans with CF, a disease
dominated by chronic neutrophilic inflammation of the airways,
and in a murine model of the disease. At concentrations
equivalent to those observed in airway secretions, HMGB1
induced neutrophil chemotactic activity through a CXCR-
dependent pathway, and a neutralizing antibody against HMGB1
caused significant reduction in chemotaxis induced by human CF
sputum and BALF from Scnn1b-Tg mice. Intratracheal instilla-
tion of HMGB1 in mice induced significant airway neutrophilia
and was accompanied by lung matrix degradation, as evidenced
by the production of PGP, a bioactive collagen degradation
product also shown to be elevated in Scnn1b-Tg mice BALF and
human CF serum. Elevated PGP was previously reported in CF
sputum (35). Although quantification of HMGB1 in serum and
airway secretions has been reported to be difficult due to its
potential to bind albumin and other extracellular proteins (36),
we were able to quantify HMGB1 in abundance in biologic
samples using both immunoblotting (compared with protein
standard) and ELISA methods.
Previous reports of HMGB1 activity have focused on its
importance as a mediator of acute inflammation of the lung,
including its role in sepsis, hemorrhagic shock, ARDS, and
ventilator-associated injury (1–3, 9, 14). Our study is the first to
suggest that HMGB1 also has a significant role in neutrophilic
inflammation in the CF lung and complements findings reported
by Kokkola and colleagues (16, 37), which showed a substantial
presence of HMGB1 in the synovial fluid of a rheumatoid arthritis
rat model, a disease also mediated by long-standing neutrophilic
inflammation. Notably, we demonstrate that HMGB1 acts as
a direct neutrophil chemoattractant, and our research supports
observations reported by Orlova and colleagues (38) who showed
Figure 2. High-mobility group box 1 (HMGB1) levels are elevated in
the lungs of Scnn1b-transgenic (Scnn1b-Tg) mice. (A) Neutrophils and
eosinophils are significantly increased in bronchoalveolar lavage fluid
(BALF) samples obtained from Scnn1b-Tg mice compared with wild-
type littermate controls. BALF samples were procured in a paired
fashion at 5 weeks of life; P , 0.005, n 5 15 per genotype. (B) HMGB1
was detected after loading 30 ml BALF aliquots and analyzed by
Western blot using sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) and immunoblot with monoclonal antibody
directed against HMGB1. HMGB1 has a calculated molecular weight
of 24.9 kD and migrates as a 29-kD band under SDS-PAGE conditions.
(C) Summary of data representing normalized densitometry of wild-
type versus Scnn1b-Tg mice; *P , 0.05 by densitometry analysis, n 5
10 per genotype. (D) HMGB1 was detected by ELISA; *P , 0.05, n 5 8
wild-type and 7 Scnn1b-Tg mice. wt 5 wild type.
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that HMGB1 induced neutrophil chemotaxis dependent on Mac-
1 (CD116/CD18) and RAGE through activation of the NF-kB
pathway. Our findings extend these results and establish that
neutrophil chemotaxis is also induced directly by HMGB1 in
a mechanism dependent on CXCR2. Given that mouse neutro-
phils, like human PMNs, expressed CXCR2, but did not exhibit
chemotaxis in response to purified HMGB1 (Figure 3E), suggests
that HMGB1 likely contributes to inflammation in Scnn1b-Tg
Figure 3. High-mobility group box 1 (HMGB1) is a potent chemoattractant for isolated human neutrophils in vitro, contributes to polymorphonuclear
leukocyte chemotaxis elicited by sputum from subjects with cystic fibrosis (CF) and from bronchoalveolar lavage fluid (BALF) of Scnn1b-transgenic
(Scnn1b-Tg) mice, and can be partially inhibited by neutralizing antibody. (A) Chemotaxis of various concentrations of recombinant human HMGB1
was compared with medium (negative control) and IL-8 (positive control). Migration was measured by quantitative photomicrograph after 1 hour
incubation and standardized to cell count found in medium control; *P , 0.005 versus medium control, n 5 5, 6SEM. (B) HMGB1 is chemotactic
rather than chemokinetic, as evidenced by inhibition of chemotaxis toward HMGB1 in the lower chamber (2,000 ng/ml) by placement of HMGB1
in the upper chamber; *P , 0.05 versus control, n 5 3 per condition, 6SEM. (C) CF sputum was evaluated alone, with anti-HMGB1 neutralizing
antibody or isotype control antibody. Medium and IL-8 positive control are provided for comparison; *P , 0.001 versus medium; **P , 0.01 versus CF
sputum; n 5 6, 6SEM. (D) BALF from Scnn1b-Tg mice was compared with wild-type littermate controls with and without the presence of anti-HMGB1
neutralizing antibody; *P , 0.01 versus control and **P , 0.05 versus Scnn1b-Tg mice, n 5 5, 6SEM. (E) HMGB1 induces human neutrophil chemotaxis
by a CXCR2-dependent mechanism, as evidenced by blockade of HMGB1 (2,000 ng/ml)-induced chemotaxis after preincubation of isolated human
neutrophils with anti-CXCR2 antibody. Neutralization with both anti-CXCR1 and anti-CXCR2 antibodies also inhibited chemotaxis. Anti-CXCR antibodies
(25 mg/ml) were preincubated with neutrophils after isolation for 45 minutes at 48C, as described in METHODS; *P , 0.05, n 5 3 per condition, 6SEM. wt 5
wild type.
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mice predominantly through indirect mechanisms, such as the
release of TNF-a and KC (through activation of inflammation by
Toll-like receptor [TLR]-2, TLR-4, and RAGE [2]) or by
augmenting other proinflammatory cytokines, as suggested by
Sha and colleagues (39). In contrast, in humans, HMGB1 exhibits
both direct (CXCR2-dependent) and indirect proinflammatory
effects.
Our study is the first report of inhibition of HMGB1-mediated
chemotaxis by antibody inhibition in biologic specimens that
also supports the potential for in vivo blockade of chemo-
attractant activity. HMGB1-dependent chemotactic activity
shown in these studies suggests that exaggerated levels, possibly
promoted by poor mucociliary clearance of necrotic cells
(40), have deleterious effects in the CF airway that may be
self-sustaining. Direct activation of PMNs by HMGB1 would be
anticipated to further contribute to airway destruction and
progression of bronchiectasis. These findings may have impli-
cations in other proinflammatory airway diseases where neu-
trophils are prominent, including chronic obstructive pulmonary
disease (41) or ischemic/reperfusion injury of the transplanted
lung (42).
Beyond the intrinsic chemotactic properties of HMGB1, these
data show that modest levels of HMGB1 in the lung can lead to
collagen matrix degradation and production of bioactive proin-
flammatory mediators, thus linking influx and activation of PMNs
by HMGB1 using a readily obtained, noninvasive measure of lung
injury. The finding that HMGB1 is also detected in the Scnn1b-Tg
model of chronic bronchitis, at levels anticipated to activate
neutrophils (33) and sufficient to induce PMN chemotaxis,
provides a mechanism by which HMGB1 could contribute to
neutrophil migration and activation, lung matrix degradation,
and liberation of PGP. We speculate that neutrophil influx by
HMGB1 through CXCR2 and activation mediated through the
NF-kB pathway may contribute to the release of bioactive
enzymes, including neutrophil elastase and matrix metallopro-
teinase 8 and 9, each previously reported to be present in PMNs
highly active in the CF lung (25, 43). Collagen degradation
induced by activation of innate immunity in the inflamed airway
results in liberation of PGP, a collagen fragment reported by our
laboratory to have proinflammatory effects through both CXCR1
and CXCR2 receptors present in neutrophils (22). Combined
with HMGB1, release of this peptide fragment provides a positive
feedback mechanism that contributes to persistent neutrophilic
inflammation in the CF lung.
Estimates of HMGB1 levels in human sputum were inversely
correlated with the duration of intravenous antibiotics in
patients with CF and APE (Figure 1D). Previous studies
indicate that appropriate antimicrobial therapy is associated
with a reduction in markers of inflammation in sputum and
serum (particularly IL-8, IL-6, and total neutrophil counts),
although not all studies have been consistent (44–46). The
inverse correlation with antimicrobial therapy in our study
further indicates the importance of HMGB1 during periods of
disease exacerbation, and suggests that HMGB1 may serve as
a biomarker for the activation of innate immunity. Moreover,
HMGB1 was intermediately elevated in outpatients with CF, in
whom neutrophilic inflammation is also evident (but to a lesser
extent), and was inversely correlated with lung function when
both outpatients and inpatients with CF were considered, which
supports the notion that extracellular HMGB1 levels are
correlated with overall disease activity and are particularly
sensitive to the presence of acute lung inflammation. The
potential indicators of CF APE are an area of significant
interest because they may be useful biomarkers for novel CF
therapeutics and assist in the clinical management of subjects
with CF (47, 48). The potential to combine the detection of
upstream mediators, such as HMGB1, IL-8, and other proteases
indicative of acute inflammation, with downstream events, such
as the liberation of PGP, might allow the monitoring of both
early and late pathways underlying lung inflammation and
improve the characterization of CF APE beyond typical clinical
criteria. The potential of HMGB1 to serve as a disease bio-
marker deserves further attention (such as evaluation of paired
samples before and after therapeutic intervention) to confirm
our initial observations and assess response to systemic antimi-
crobial therapy.
Inhibitors of HMGB1 are currently being developed for
application in sepsis and other inflammatory diseases. In CF, an
intervention that blocks the dysregulated activation of the
innate immune system could potentially ameliorate excessive
chronic neutrophilic inflammation that contributes to disease
progression (18, 20, 49). Elevated HMGB1 levels in the Scnn1b-
Tg mouse model, without acquisition of P. aeruginosa, suggests
its importance in chronic inflammation that is due to mucus
stasis, possibly precipitated by the presence of necrotic cellular
debris detectible in the airways of these mice (21). Inhibition of
inflammatory mediators that contribute to the CF inflammatory
phenotype before the onset of bacterial colonization may be
a more suitable therapeutic target than conventional cytokines
and other mediators that become elevated primarily after the
onset of chronic infection, when immune suppression could carry
additional risks (50). If inhibition of this pathway could reduce
infection-independent inflammation, inhibitors of HMGB1 may
have a more favorable toxicity profile, thus avoiding the potential
worsening of infection associated with potent inhibition of
proinflammatory (and antiinfective) pathways, as reported with
LTB4 antagonists (51, 52).
Although P. aeruginosa infection is not required, as evi-
denced by chemotaxis in both CF sputum and murine BALF
sample (Figure 3), these data do not rule out a modulatory role
Figure 4. Intratracheal injection of recombinant human high-mobility
group box 1 (HMGB1) induces dose-dependent influx of neutrophils in
bronchoalveolar lavage fluid. HMGB1 neutrophil chemotactic activity was
observed in (A) wild-type BALB/c mice or (B) endotoxin-resistant C3H/HeJ
mice. Mice were killed 24 hours after HMGB1 instillation; *P , 0.05, n 5
3–6 per condition, 6SEM. PMN 5 polymorphonuclear leukocytes.
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Figure 5. Intratracheal instillation of high-mobility group box 1
(HMGB1) triggers matrix collagen degradation and release of proline-
glycine-proline (PGP) peptide, which is also found to be elevated in
Scnn1b-transgenic (Scnn1b-Tg) mice bronchoalveolar lavage fluid
(BALF) and in the serum of patients with cystic fibrosis (CF). (A)
Instillation of HMGB1 at dosage sufficient to induce airway poly-
morphonuclear leukocyte influx also induces production of the colla-
gen fragment PGP. Recombinant human HMGB1 (25 mg) was instilled
in C3H/HeJ mice, which were then killed 24 hours later for BALF; *P ,
0.05, n 5 3 per condition, 6SEM. (B) Using electrospray ionization–
liquid chromatography followed by tandem mass spectrometry, PGP
was detected as a peak with retention time at 3.1 seconds and
molecular weight splits of 270/70 and 270/116 (270/70 split shown
in top panel; bold peak represents PGP standard [100 pg/ml]). The
same peak was observed in BALF of Scnn1b-Tg mice (middle panel,
representative section) but not in the BALF from wild-type littermate
controls (bottom panel). (C) PGP was detected by electrospray ioniza-
tion–liquid chromatography followed by tandem mass spectrometry
and quantified by the relative standard curve method. BALF samples
were obtained in a paired fashion from 5-week-old, sex-matched mice;
*P , 0.005, n 5 11 per genotype. (D) Serum samples obtained from
normal nonsmoking individuals and subjects with CF hospitalized for
acute pulmonary exacerbation were analyzed for PGP. Results were
normalized to the expression seen in normal subjects; *P , 0.02, n 5
10 normal subjects, 14 subjects with CF, 6SEM.
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for bacterial infection on the activity of HMGB1-mediated
chemotaxis. Additional studies are needed that examine the
role of P. aeruginosa infection and resultant HMGB1 release, to
better define this pathway in CF inflammation. Recent reports
by Tian and colleagues (53) and Rouhiainen and colleagues (54)
indicate that immune activation and cytokine release induced
by HMGB1 is significantly enhanced after tight binding to
bacterial DNA, prokaryotic lipids, and other bacterial sub-
stances that are present in high quantities in infected and
colonized CF sputum (55, 56). Not surprisingly, whereas block-
ing HMGB1 signaling caused a significant reduction in chemo-
taxis, our in vitro observations indicate that this is not the only
pathway relevant to neutrophil influx (z75% of neutrophil
influx remained unabated) and may indicate the importance of
other inflammatory mediators such as IL-8 or PGP in these
specimens.
In summary, our study shows that HMGB1 is elevated in
subjects with CF and in an animal model of the disease, that
it is directly chemotactic for neutrophils through a CXCR-
dependent mechanism, and that HMGB1 activity can be
blocked by antibody binding in vitro. HMGB1 also induces
collagen matrix degradation, resulting in a positive feedback
loop that is expected to perpetuate and propagate neutrophilic
inflammation through liberation of the proinflammatory poly-
peptide PGP. HMGB1 appears to be an important inflamma-
tory modulator in airway secretions of subjects with CF and
a murine model of CF inflammation. Studies using neutralizing
anti-HMGB1 antibodies or other antagonists are warranted to
confirm its pathogenic role in sterile airway inflammation in
Scnn1b-Tg mice. If confirmed, neutralization of HMGB1 and/or
PGP may represent potential therapeutic targets to treat the
persistent chronic inflammation that is prominent in CF.
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